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Abstract
Background: Excessive accumulation of extracellular matrix (ECM) proteins is the hallmark of fibrotic diseases,
including skin fibrosis. This response relies on the activation of dermal fibroblasts that evolve into a pro-fibrogenic
phenotype. One of the major players in this process is the cytokine transforming growth factor-β (TGF-β).
MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression affecting a
wide range of pathophysiological events including fibrogenesis. MicroRNA-9-5p (miR-9-5p) has been shown to exert
a protective role in lung and peritoneal fibrosis. This study aimed to evaluate the role of miR-9-5p in skin fibrosis.
Results: miR-9-5p is up-regulated in TGF-β1-treated human dermal fibroblasts (HDFs). In silico identification of
miR-9-5p targets spotted the type II TGF-β receptor (TGFBR2) as a potential TGF-β signaling-related effector for this
miRNA. Consistently, over-expression of miR-9-5p in HDFs down-regulated TGFBR2 at both the mRNA and protein
levels and reduced the phosphorylation of Smad2 and the translocation of Smad2/3 to the nucleus. In keeping,
over-expression of miR-9-5p significantly delayed TGF-β1-dependent transformation of dermal fibroblasts,
decreasing the expression of ECM protein collagen, type I, alpha 1 (Col1α1), and fibronectin (FN), the amount of
secreted collagen proteins, and the expression of the archetypal myofibroblast marker alpha-smooth muscle actin
(α-SMA). By contrast, specific inhibition of miR-9-5p resulted in enhanced presence of fibrosis markers. The
expression of miR-9-5p was also detected in the skin and plasma in the mouse model of bleomycin-induced
dermal fibrosis. Using lentiviral constructs, we demonstrated that miR-9-5p over-expression was also capable of
deterring fibrogenesis in this same model.
Conclusions: miR-9-5p significantly prevents fibrogenesis in skin fibrosis. This is mediated by an abrogation of
TGF-β-mediated signaling through the down-regulation of TGFBR2 expression in HDFs. These results may pave the
way for future diagnostic or therapeutic developments for skin fibrosis based on miR-9-5p.
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Background
Fibrosis is a process characterized by the excessive synthe-
sis and deposition of extracellular matrix (ECM) proteins.
It can affect several organs leading to the progressive
replacement of functional tissue. In the skin, fibrosis
develops in the dermis, the connective tissue layer
under the basement membrane and the epidermis and
is mainly composed by ECM. The latter is made of fi-
brous structural proteins such as collagen and elastin,
adhesive glycoproteins (fibronectin (FN) and laminin),
proteoglycans, and hyaluronan. Together, they provide
structural and biomechanical support to cellular com-
ponents, mostly fibroblasts. ECM remodeling is medi-
ated by lysyl oxidases (LOXs) that cross-link collagens
and elastins through oxidative deamination of lysine
residues, whereas ECM dynamic degradation is mainly
mediated by the endopeptidase matrix metallopro-
teases (MMPs) [1]. Skin fibrosis is a hallmark feature
of several diseases, including systemic sclerosis (SSc),
keloids, hypertrophic scars, and graft-versus-host dis-
ease [2]. To date, no therapy has been shown to reverse
or arrest the progression of skin fibrosis, even though
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it has a profound impact on the duration and quality of
life. For instance, systemic sclerosis affects 100,000
people in the USA with a median survival time of
11 years [3]. Despite their different etiological origin,
these diseases converge in a common aberrant wound
repair response [4]. Transforming growth factor-β
(TGF-β) and other pro-fibrotic cytokines, which are re-
leased in this persistent inflammation response, lead to
the activation, proliferation, and differentiation of fi-
broblasts into myofibroblasts, the cell type ultimately
responsible for the synthesis, remodeling, and contrac-
tion of ECM [5]. Myofibroblasts are commonly identi-
fied by the expression of alpha-smooth muscle actin
(α-SMA), and they are characterized by a pronounced
rough endoplasmic reticulum, stress fibers, and a large
nucleus. Although they mainly derive from resident fi-
broblasts, they can be recruited from skin-derived pre-
cursors and bone marrow fibrocytes. In some tissues,
epithelial and endothelial to mesenchymal transition
(EMT and EndoMT, respectively), vascular smooth
muscle cells, and pericytes may also contribute to
fibroblast accumulation [6].
One of the major mediators in the fibrogenic pro-
cesses, TGF-β, has been also implicated in the patho-
genesis of skin fibrotic disorders [7]. SSc patients show
high levels of plasma TGF-β, and fibroblasts from these
patients display elevated levels of TGF-β expression [8,
9]. In several established animal models of SSc, TGF-β
acts as a key mediator in fibrosis development and the
reduction of TGF-β expression by several therapeutic
strategies shows anti-fibrotic effects [10–13]. TGF-β
acts by interacting with a heteromeric complex of
transmembrane serine/threonine kinase receptors, the
type I TGF-β receptor (TGFBR1) and type II TGF-β re-
ceptor (TGFBR2). The activation of the type I receptor
leads to the propagation of signaling by at least two
independent routes: the Smad-dependent canonical
pathway and the Smad-independent or non-canonical
pathways. In the first one, the activation of TGFBR1
leads to phosphorylation of receptor-specific Smad (R-
Smad) proteins, Smad2 and Smad3. Upon phosphoryl-
ation, R-Smads together with the common-mediator
Smad (co-Smad), Smad4, translocate to the nucleus,
where they interact with other transcription factors
(co-factors) to regulate transcriptional responses [14].
Consequently, dysregulated TGF-β signaling has been
reported in skin fibrotic diseases. It was reported that
fibroblasts from SSc patients show an increase of TGF-
β receptors and Smad2/3 nuclear translocation, while
Smad7 expression is reduced [15]. In keloid fibroblasts,
increased expression of TGFBR1 and TGFBR2 and in-
creased phosphorylation of Smad3 are present, sup-
porting a central role for TGF-β/Smad signaling in its
pathogenesis [16].
MicroRNAs (miRNAs) are a group of small (~19–24
nucleotides), non-coding RNAs that modulate gene ex-
pression by interacting with the 3′-untranslated region
(3′-UTR) of the corresponding target gene messenger
RNA (mRNA) [17, 18]. In most circumstances, miRNAs
are believed to either repress mRNA translation or re-
duce mRNA stability [17, 18]. miRNAs are proposed to
promote cellular robustness and homeostasis, and hence,
alterations of miRNA expression can occur as a response
to stress-related phenomena in a variety of diseases [19].
These small RNAs have been described to play a major
role in the initiation and progression of numerous dis-
eases, including the fibrosis of several organ systems,
such as the skin, heart, liver, kidney, and lungs [20, 21].
In the context of skin fibrosis, it is well illustrated that
miRNAs are involved in this disease by regulating TGF-
β signaling, ECM synthesis, and degradation, by control-
ling the proliferation and differentiation of myofibro-
blasts. They have been also implicated in the EMT
process as well as in the pathogenesis and maintenance
of skin fibrosis [3, 22]. Among these, miR-29 has been
extensively studied and is the best characterized negative
regulator of ECM protein synthesis by directly targeting
collagen, type I, alpha 1 (Col1α1) mRNA [23–26]. SSc
patient-derived skin fibroblasts showed a consistent
down-regulation of miR-29 [27], and over-expression of
this miRNA has been proposed as a potent anti-fibrotic
strategy [23, 25]. In addition to miR-29, several other
miRNAs are known to negatively regulate collagen ex-
pression, such as let-7a and miRNA-196a, both down-
regulated in SSc [28, 29]. The expression of miR-21 was
increased in both SSc skin tissues and fibroblasts [26].
This miRNA is up-regulated by TGF-β signaling, and
miR-21 in turn reduces the expression of Smad7, releas-
ing the inhibition of the TGF-β pathway, thus creating a
feed-forward loop [30]. Let-7g and miR-23b up-regulate
TGFBR2 expression and are associated with SSc [31],
while miR-140-5p, miR-17-5p, and miR-20 have an op-
posite effect, thus resulting in hypertrophic scars [32]. In
the clinical setting, miRNAs may be considered potential
biomarkers due to their stability and relatively easy de-
tection in biological fluids. Importantly, due to the poor
efficacy of available treatments like cyclophosphamide,
prednisolone, or methotrexate against skin fibrosis, the
development of new therapeutic approaches is urgent.
miRNA-targeted therapies attempt to increase the expres-
sion of anti-fibrotic miRNAs by miRNA mimics or viral
vectors with built-in miRNA precursors or to reduce the
expression of pro-fibrotic miRNAs using anti-miRNAs,
sponges, erasers, and masks [33].
We have recently reported the protective role of
microRNA-9-5p (miR-9-5p) in lung and peritoneal fibrosis
[34]. Human miR-9 is encoded by three distinct genomic
loci, located in chromosomes 1, 5, and 15, generating
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three mature miR-9 species with identical sequences. This
miRNA is broadly conserved in animals and was first
identified as a crucial regulator for the development and
maturation of the nervous system in vertebrates [35] and
in human brain pathologies [36, 37] as well as in tumors
outside the nervous system [38–40]. Noteworthy, there is
no information, to our knowledge, implicating miR-9-5p
in skin fibrosis. This study aimed to analyze the potential
role of miR-9-5p in skin fibrosis by using human dermal
fibroblasts (HDFs) in culture and a mouse model of
bleomycin-induced skin fibrosis. We found that miR-9-5p
prevents the transformation of human fibroblasts into
myofibroblasts by blocking TGF-β signaling and signifi-
cantly attenuates bleomycin-induced skin fibrosis.
Results
miR-9-5p is induced by TGF-β1 and reduces TGFBR2
expression in human dermal fibroblasts
To study the possible implication of miR-9-5p in skin fi-
brosis, HDFs were treated with 5 ng/ml TGF-β1 for the
indicated times and its expression was analyzed by quan-
titative reverse transcription-polymerase chain reaction
(qRT-PCR). TGF-β1 induced a time-dependent over-
expression of this miRNA, with an increase of more than
20 times after 24-hour (h) treatment compared to con-
trol cells (Fig. 1a). This result suggests the potential in-
volvement of miR-9-5p in the TGF-β1-related signaling
responses in dermal fibroblasts. TGFBR2 has been previ-
ously validated as a target of miR-9-5p [34]. In silico
analysis of the 3′-UTR shows that it bears two seed tar-
get sites for miR-9-5p, one poorly and the other well
conserved across several vertebrate species. To validate
if miR-9-5p also modulates TGFBR2 expression in HDFs
and to determine if this miRNA affects its mRNA stabil-
ity and/or its translation, we performed gain-of-function
experiments. Over-expression of miR-9-5p in dermal fi-
broblasts resulted in a significant decrease of about 50 %
in both TGFBR2 mRNA and protein levels (Fig. 1b, c),
indicating the negative regulation of TGFBR2 by miR-9-
5p in HDFs. TGFBR1 is also an in silico predicted target
of miR-9-5p. However, the over-expression of this
miRNA did not alter TGFBR1 mRNA levels (Additional
file 1: Figure S1A).
miR-9-5p attenuates TGF-β1 pro-fibrogenic signaling in
human dermal fibroblasts
To assess if miR-9-5p-related reduction in TGFBR2 ex-
pression was associated with a decrease in the TGF-β-
induced pro-fibrogenic transformation of fibroblasts,
HDFs were transfected with 40-nM precursor of miR-9-
5p (pre-miR-9-5p) and incubated with 5 ng/ml TGF-β1
for different times. As shown in Fig. 2, over-expression
of miR-9-5p significantly abolished TGF-β1-induced
transcription of α-SMA, Col1α1, and FN after 24- and
48-h treatments (Fig. 2a–c). Noticeably, the abrogation
was almost complete in the case of Col1α1 (Fig. 2b).
Similarly, increasing levels of miR-9-5p strongly reduced
TGF-β1-induced α-SMA, FN, and collagen type I-V
Fig. 1 miR-9-5p is induced by TGF-β1 and reduces TGFBR2 expression. a miR-9-5p expression was assayed by qRT-PCR in HDFs stimulated with
TGF-β1 (5 ng/ml) at the indicated times. b qRT-PCR analysis for mRNA expression of TGFBR2 in HDFs transfected with 40-nM pre-miR-9-5p or
pre-miR-NC. c Western blot analysis (left) and quantification (right) of TGFBR2 expression in HDFs transfected with 40-nM pre-miR-9-5p or
pre-miR-NC (a.u., arbitrary units). The bar graph shows values after correction by GAPDH expression and normalized to control conditions.
The bar graphs show mean ± SEM of three independent experiments, *P < 0.05 and ***P < 0.001 compared to control cells
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Fig. 2 (See legend on next page.)
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protein abundance (Fig. 2d–f ), as well as the amount of
α-SMA-positive fibroblasts in the presence of TGF-β1
for 24 h (Fig. 2g). These data suggest that miR-9-5p can
prevent the TGF-β1-dependent differentiation of dermal
fibroblasts into myofibroblasts by regulating the TGF-β
signaling pathway. Consistently, miR-9-5p significantly
abrogated the phosphorylation of Smad2 and the trans-
location of Smad2/3 to the nucleus that usually occurs
after TGF-β1 stimulation, visible after both short and
prolonged periods of exposure (Fig. 3a–c, Additional file
1: Figure S1C), without affecting the expression of the
inhibitory Smad, Smad7 (Additional file 1: Figure S1B).
Loss-of-function experiments with the miR inhibitor-9
showed an up-regulation of the TGF-β1-induced tran-
scription of α-SMA, Col1α1, and FN after 24-h treatment
(Fig. 4a–c). This increase was also observed on α-SMA
and FN protein levels (Fig. 4d, e). Altogether, these results
suggest that miR-9-5p exerts an inhibitory effect on TGF-
β1-dependent fibroblast differentiation, which is mediated,
at least in part, by the negative regulation of the Smad-
dependent pathway related to TGF-β signaling.
miR-9-5p prevents bleomycin-induced skin fibrosis
The above results prompted us to investigate whether
the increased levels of miR-9-5p in HDFs after TGF-β
treatment were recapitulated in the SSc murine model
of bleomycin-induced skin fibrosis. To determine the ex-
pression level of miR-9-5p in skin samples of bleomycin-
treated mice, bleomycin was injected subcutaneously
and its effect analyzed after different time periods. Ana-
lysis by qRT-PCR showed that miR-9-5p was significantly
up-regulated approximately threefold in skin samples
from animals after 28 days of bleomycin treatment com-
pared to those from untreated animals (Fig. 5a), indicating
the possible implication of this miRNA in SSc. Recent
studies indicate that miRNAs in body fluids can represent
novel biomarkers for various diseases [41]. These circulat-
ing miRNAs are found to be remarkably stable even under
harsh conditions of temperature or pH [42]. Interestingly,
circulating miRNAs are protected from endogenous
RNase activity [43], possibly due to packaging in micro-
particles or apoptotic bodies, to association with RNA-
binding proteins or by linkage to high-density lipoproteins
[44]. Furthermore, secreted miRNAs can be delivered into
recipient cells where they function as endogenous miR-
NAs, simultaneously regulating multiple target genes or
signaling pathways [44, 45]. Thus, serum miRNA levels
may not merely be secreted from apoptotic cells but may
exert some biological effects in cell-to-cell communica-
tion. We evaluated the possibility that plasma miR-9-5p
levels can be a disease marker in the mouse model of SSc.
An increase of miR-9-5p expression of approximately six-
fold was observed in plasma samples from mice after
28 days of bleomycin treatment compared to those from
untreated animals (Fig. 5b), suggesting that this miRNA
could be a novel biomarker for SSc. To determine the pos-
sible effect of this miRNA in the development of experi-
mental dermal fibrosis, lentiviral vectors expressing a
scramble negative control construct (lenti-SC) or miR-9-
5p (lenti-miR-9) were subcutaneously administrated in
mice 4 days before bleomycin administration. To analyze
the extent of skin fibrosis induced by bleomycin, histo-
logical analysis was performed. An increase in dermal
thickness and accumulation of collagen replacing the sub-
cutaneous adipose layer were observed in mice injected
subcutaneously with bleomycin for 4 weeks compared to
control mice, as examined by hematoxylin and eosin
(H&E) and Masson’s trichrome staining, respectively
(Fig. 5c). Importantly, pre-administration of lentiviral vec-
tors carrying miR-9-5p effectively attenuated dermal
thickness (Fig. 5d). Consequently, lenti-miR-9 administra-
tion also significantly reduced the elevated expression of
ECM-related genes, such as Col1α1 and FN, elicited by
bleomycin administration (Fig. 5e, f ). All these results to-
gether suggest a possible protective role for miR-9-5p in
skin fibrosis and a possible use of this miRNA as a diag-
nostic marker for this condition.
Discussion
Given our previously reported observations on the anti-
fibrotic action of miR-9-5p in lung and peritoneal fibro-
sis, the goal of this study was to determine whether
miR-9-5p might play a similar role in the prevention of
skin fibrosis and fibroblast fibrogenic transformation.
(See figure on previous page.)
Fig. 2 miR-9-5p over-expression abrogates TGF-β1-induced differentiation of human dermal fibroblasts into myofibroblasts. a–c qRT-PCR analysis
for mRNA expression of α-SMA (a), Col1α1 (b), and FN (c) in HDFs transfected with 40-nM pre-miR-9-5p or pre-miR-NC and treated with TGF-β1
(5 ng/ml) for the indicated times. d Western blot analysis (top) and quantification (bottom) of α-SMA levels in HDFs transfected with 40-nM
pre-miR-9-5p or pre-miR-NC and treated with TGF-β1 (5 ng/ml) for the indicated times (a.u., arbitrary units). The bar graph shows values after
correction by GAPDH expression and normalized to control conditions. e Western blot analysis (top) and quantification (bottom) of FN levels in
HDFs transfected with 40-nM pre-miR-9-5p or pre-miR-NC and treated with TGF-β1 (5 ng/ml) for the indicated times (a.u., arbitrary units). The
bar graph shows values after correction by GAPDH expression and normalized to control conditions. f Sircol assay of secreted collagen proteins
I-V was done in HDFs transfected with 40-nM pre-miR-9-5p or pre-miR-NC and treated with TGF-β1 (5 ng/ml) for the indicated times (a.u., arbitrary
units). g Immunofluorescence staining of α-SMA (green) in HDFs treated with TGF-β1 (5 ng/ml) for 48 h after transfection with 40-nM pre-miR-9-5p or
pre-miR-NC. Nuclei were stained with DAPI (blue). Scale bars: 100 μm. The bar graphs show mean ± SEM of three independent experiments, *P < 0.05,
**P < 0.01, and ***P < 0.001 compared to control cells and #P < 0.05 and ##P < 0.01 compared to its corresponding negative control time point
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We found that miR-9-5p expression was up-regulated
20-fold in HDFs after their treatment with TGF-β1. In
keeping, miR-9-5p has been reported to be up-regulated
in dermal fibroblasts isolated from SSc patients [28] and
in TGF-β-treated lung fibroblasts and omentum-derived
mesenchymal cells [34]. This regulation of miR-9-5p by
TGF-β could potentially occur via primary miRNAs (pri-
miRNAs) due to the in silico identification of at least
two Smad-binding elements (SBEs) in the putative pro-
moter region of miR-9-1 and at least another two for
miR-9-3 [34]. However, other regulatory mechanisms
cannot be excluded. TGF-β is not only able to regulate
gene expression at the level of transcription but also to
control Drosha-mediated miRNA processing [46]. In
addition, it is possible that other specific transcription
factors like REST, which mediate the expression of this
miRNA in other cell types, could be regulated by TGF-β
and may participate in this response [47]. TGFBR2 was
previously proposed by our group as a direct target of
miR-9-5p not only by in silico analysis and further mo-
lecular validation but also by the reduced action of this
miRNA in the presence of exogenously enhanced ex-
pression of this protein [34]. TGFBR2 is a transmem-
brane serine/threonine kinase receptor necessary for
(See figure on previous page.)
Fig. 3 miR-9-5p attenuates Smad-dependent TGF-β signaling. a Western blot analysis (left) and quantification (right) of pSmad2 protein levels in
HDF cells transfected with 40-nM pre-miR-9-5p or pre-miR-NC and treated with TGF-β1 (5 ng/ml) at the indicated times (a.u., arbitrary units). The
bar graph shows values after correction by Smad2 expression and normalized to control conditions. b Immunofluorescence staining of Smad2/3
(green) in HDFs treated with TGF-β1 (5 ng/ml) for 30 min after transfection with 40-nM pre-miR-9-5p or pre-miR-NC. Nuclei were stained with
DAPI (blue), and F-actin was stained with phalloidin (red). Scale bars: 100 μm. c Western blot analysis after nuclear/cytoplasmic fractionation (left)
and quantification (right) of Smad2/3 protein levels in HDF cells transfected with 40-nM pre-miR-9-5p or pre-miR-NC and treated with TGF-β1
(5 ng/ml) at the indicated times (a.u., arbitrary units). The bar graph shows values after correction by GAPDH (cytosol) and LMNA (nucleus) expres-
sion and normalized to control conditions. All bar graphs represent mean ± SEM of three independent experiments, **P < 0.01 compared to con-
trol cells and #P < 0.05 compared to its corresponding negative control time point
Fig. 4 Inhibition of miR-9-5p enhances TGF-β1-induced transformation of human dermal fibroblasts into myofibroblasts. a–c qRT-PCR analysis for
mRNA expression of α-SMA (a), Col1α1 (b), and FN (c) in HDF transfected with 40-nM miR inhibitor-NC or miR inhibitor-9 and treated with TGF-β1
(5 ng/ml) for the indicated times. d Western blot analysis (left) and quantification (right) of α-SMA and FN levels in HDF transfected with 40-nM miR
inhibitor-9 or miR inhibitor-NC (control) and treated with TGF-β1 (5 ng/ml) for the indicated times (a.u., arbitrary units). The bar graphs show
values after correction by GAPDH expression and normalized to control conditions. e Western blot analysis (top) and quantification (bottom)
of FN levels in HDF transfected with 40-nM miR inhibitor-9 or miR inhibitor-NC (control) and treated with TGF-β1 (5 ng/ml) for the indicated
times (a.u., arbitrary units). The bar graph shows values after correction by GAPDH expression and normalized to control conditions. The bar
graphs show mean ± SEM of three independent experiments, *P < 0.05, **P < 0.01, and ***P < 0.001 compared to control cells and #P < 0.05
and ##P < 0.01 compared to their corresponding negative control time point
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TGF-β signal transduction whose 3′-UTR contains two
target sites for miR-9-5p, of which one is highly con-
served among vertebrates and has been implicated in
the development of fibrotic processes. In the skin,
TGFBR2 expression is increased in SSc fibroblasts as
well as in keloids [15, 16]. Consistently, miR-9-5p down-
regulated TGFBR2 expression at both the mRNA and
protein levels by approximately 50 % in HDFs. This sug-
gests that both mRNA translation repression and deg-
radation mechanisms could be involved in the negative
regulation of the expression of TGFBR2 by miR-9-5p.
TGFBR2 down-regulation constitutes one of the plaus-
ible mechanisms to explain the anti-fibrotic action of
miR-9-5p. However, it is possible that other targets re-
lated with TGF-β signaling pathway and/or ECM synthe-
sis can also contribute to this outcome. Examination of
miR-9-5p function revealed that over-expression of this
miRNA followed by treatment with TGF-β1 decreased
the abundance of α-SMA-positive fibroblasts and the α-
SMA and ECM-related gene, Col1α1 and FN, expression.
Fig. 5 miR-9-5p prevents bleomycin-induced skin fibrosis. a, b miR-9-5p expression was assayed by qRT-PCR in the skin (a) and plasma (b) after
daily subcutaneous injections of 10 μg bleomycin for 14 and 28 days. c H&E staining and Masson’s trichrome blue staining for collagen in skin
samples from mice administered 1 × 108 ifu of lenti-SC (control) or lenti-miR-9 for 4 days followed by daily subcutaneous injections of 10 μg bleomycin
for 4 weeks. Scale bars: 100 μm. d Quantitative evaluation of dermal thickness from the same samples as in (c), calculated as the ratio between dermis
and total skin thickness. e, f qRT-PCR analysis for mRNA expression of Col1α1 (e) and FN (f) in skin samples from mice administered 1 × 108 ifu
of lenti-SC (control) or lenti-miR-9 for 4 days followed by daily subcutaneous injections of 10 μg bleomycin for 4 weeks. All bar graphs represent
mean ± SEM (n = 6 mice in each group), *P < 0.05 and ***P < 0.001 compared to mice given control lentivirus and saline-treated and #P < 0.05
compared to mice given control lentivirus and bleomycin-treated
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The higher degree of inhibition of Col1α1 transcription
compared to that of FN could be attributed to the fact that
Col1α1 is a potential direct target of miR-9-5p according
to TargetScan database [48]. Moreover, increasing levels
of miR-9-5p also abrogated Smad2 phosphorylation and
nuclear translocation of Smad2/3. Additionally, miR
inhibitor-9 increased TGF-β1-induced expression of α-
SMA, Col1α1, and FN. Consistently, Smad-dependent
genes such as Col1α1 resulted more affected in vivo and
in vitro than those regulated by Smad-independent path-
ways, including FN [49–51]. As an individual miRNA may
modulate multiple target genes, the potential effect of
miR-9-5p on other targets aside from TGFBR2 down-
regulation cannot be excluded as part of the anti-fibrotic
response. Although we excluded the effect of miR-9-5p on
TGFBR1, other potential in silico TGF-β-related targets
such as transforming growth factor, beta-induced
(TGFBI), Smad4, or NADPH oxidase 4 (NOX4) remain as
potential unexplored proteins whose functional inhibition
could account for part of the observed effects. Of interest,
NOX4 is involved in the generation of reactive oxygen
species (ROS) that contribute to the activation of latent
TGF-β [52]. Moreover, it is conceivable that the inhibition
of this signaling pathway could have several side effects on
other biological processes modulated by TGF-β. Addition-
ally, other miR-9-5p-predicted target genes implicated in
alternative signaling activated during skin fibrosis, such as
the Wnt/β-catenin pathway, or related to the inflamma-
tory immune response may also form part of the mecha-
nisms underlying miR-9-5p action. In this regard,
reported targets of miR-9 in other cell lines such as E-
cadherin or the transcription factor SOX2 have been
shown to regulate the Wnt pathway [53, 54]. Similarly,
MMP-13 and MMP-14 are validated miR-9-5p targets
that are involved in ECM degradation [55, 56]. In consist-
ence with in cellulo results and beyond the caveats in the
mouse model to reproduce some skin fibrotic diseases
[57], by using lentiviral vectors containing miR-9-5p pre-
cursors, we found significant abrogation of dermal fibro-
genesis. Histological and expression analysis revealed that
in vivo miR-9-5p over-expression promoted attenuation of
the bleomycin-induced increase in dermal thickness mea-
sured by accumulation of collagen.
Results from the present study suggest that TGF-β1-
induced miR-9-5p up-regulation functions as a negative
feedback loop in the regulation of TGFBR2 expression
in an attempt to reduce the excessive pro-fibrotic signals
promoted by TGF-β1 (Fig. 6). This response is however
unable to completely counteract fibroblast transform-
ation and skin fibrosis development. Triggering of simi-
larly protective responses seems to underlie the action of
other miRNAs like miR-146a, which targets SMAD4
[58]. One reason by which TGF-β1-induced increase in
miRNA levels may fail to prevent human dermal fibro-
blast activation is probably related to the relatively
smaller increase of miR-9-5p after TGF-β1 stimulation
compared with the magnitude of the response during
miR-9-5p over-expression. The level of miR-9-5p was in-
creased 20-fold after treatment with TGF-β1 whereas its
levels augmented 40-fold after in vitro transfection (data
not shown). It is also possible that biologically relevant
up-regulation of miR-9-5p may occur at a later stage
than α-SMA expression after TGF-β1 stimulation, thus
hampering an effective prevention of this crucial pro-
fibrogenic event. Other potential explanations for this
limited action include the activation of TGF-β1-
independent pro-fibrogenic stimuli, alternative TGF-β1
signaling mediated by receptors other than TGFBR2,
and/or signaling through molecules different from
Smads. The capacity of miR-9-5p to inhibit the pro-
fibrogenic transformation induced by TGF-β1 not only
in skin fibrosis but also in pulmonary fibroblasts and
peritoneal mesothelial cells [34] confers miR-9-5p a
more general counter-regulatory role in organ fibrosis.
As TGF-β blockers are not devoid of serious unwanted
effects and inhibitory molecules directed towards its in-
hibition may involve pleiotropic effects, it is tempting to
speculate that miR-9-5p could represent an advanta-
geous therapeutic alternative. Nevertheless, off-target ef-
fects cannot be excluded, and only large in vivo studies
Fig. 6 TGF-β1 induces miR-9-5p expression in an attempt to self-limit the promotion of a skin fibrotic program. Over-expression of miR-9-5p in
dermal fibroblasts blocks TGFBR2 expression, preventing myofibroblast differentiation and skin fibrosis
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will help to confirm the safety and specificity of miR-9-
5p. These particular data in the skin pave the way to ex-
plore miR-9-5p as a therapeutic agent. Perhaps in the fu-
ture, topical miRNA modulators may be of substantive
use in dermatology, similarly to the promising P144 (a
peptide inhibitor of TGF-β1) whose topical application
ameliorates bleomycin-induced skin fibrosis [59].
In addition, miRNAs have been recently reported to
circulate in body fluids representing a non-invasive bio-
marker in the diagnosis, prognosis, and evaluation of skin
fibrosis [3]. We found that plasma levels of miR-9-5p in
the bleomycin-induced skin fibrosis model were signifi-
cantly increased. Further correlation between miR-9-5p in
skin and/or plasma level and skin fibrosis degree in skin fi-
brotic connective tissue disorders will determine its poten-
tial use as a biomarker. In the skin, the expression of
miRNA-7 and miRNA-196a in serum have been shown to
inversely correlate with the duration of SSc [28, 60].
In summary, this study supports that miR-9-5p has
anti-fibrotic effects in dermal fibroblasts through the
down-regulation of the TGF-β pathway via TGFBR2 si-
lencing and provides a novel potential strategy to man-
age cutaneous fibrotic diseases.
Conclusions
We report that miR-9-5p expression levels are increased
in TGF-β-activated human dermal fibroblasts, while the
over-expression of this miRNA abrogates TGF-β signal-
ing through the down-regulation of TGFBR2 expression
in these cells. miR-9-5p is also up-regulated in skin and
plasma samples from the bleomycin mouse model and
shows an anti-fibrotic effect in skin fibrosis, thus provid-
ing a novel potential strategy to manage cutaneous fi-
brotic diseases.
Methods
Cell culture and treatments
Human dermal fibroblasts (HDFs) from the American
Type Culture Collection (ATCC catalog # PCS-201-012,
lot # 58732338) and Invitrogen (Catalog # C-013-5C, lot
# 200706-833) were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) containing 10 % (volume/volume
(vol/vol)) fetal bovine serum (FBS) (HyClone Laboratories,
Logan, UT) and supplemented with L-glutamine 2 mM
(Life Technologies, CA, USA.) and 1 % (vol/vol) penicillin/
streptomycin (Gibco, Rockville, MD). They were kept at
37 °C in the presence of 5 % CO2. Treatments with hu-
man recombinant TGF-β1 (R&D Systems, Minneapolis,
MN) were performed after serum-free starvation of
HDFs for 12 h.
miRNA target prediction bioinformatics tools
Three different and independent online target predic-
tion databases (TargetScan: http://www.targetscan.org/;
miRanda: http://www.microrna.org/; and miRwalk: http://
zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk/) were used
to identify in silico miR-9-5p targets.
Transfection procedures
HDFs were seeded into 60-mm culture dishes to
reach a confluence of 70 %. Where and as indicated,
40-nM pre-miR miRNA precursor of miR-9-5p (pre-
miR-9-5p) (AM17100, Ambion, Carlsbad, CA) or
40 nM of a non-targeting sequence pre-miR miRNA
precursor negative control #1 (pre-miR-NC) (AM17110,
Ambion, Carlsbad, CA), miR inhibitor-9, miR inhibitor-
NC (4464088, Ambion Company, USA), and 0.8 %
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) were
separately mixed in 500 μl of Opti-MEM (Gibco, Grand
Island, NY) for 5 minutes (min). Then, the two
mixtures were combined and incubated at room
temperature for 20 min. The lipofectamine-pre-miRNA
mixture was added to the cells and incubated at 37 °C
for 6 h. Subsequently, 5 ml fresh medium containing
10 % FBS was added to the culture dishes, and the cells
were maintained in culture until used for subsequent
experiments.
Western blotting
Cells were washed in phosphate-buffered saline (PBS)
and lysed in 150 μl RIPA lysis buffer containing 150 mM
NaCl, 0.1 % sodium dodecyl sulfate (SDS), 1 % sodium
deoxycholate, 1 % NP-40, and 25 mM Tris-HCl pH 7.6,
in the presence of protease (Complete, Roche Diagnos-
tics, Mannheim, Germany) and phosphatase inhibitors
(Sigma-Aldrich, St. Louis, MO). Cells were harvested by
scraping, and the samples were clarified by centrifuga-
tion at 13,000 rpm for 15 min at 4 °C. A cell fraction-
ation kit (Abcam, Cambridge, USA) was used to isolate
cytosolic and nuclear fractions. Protein concentration
was measured with the BCA assay (Thermo Scientific,
Rockford, IL, USA). Equal amounts of protein (10–
50 μg) from the total extract were separated by electro-
phoresis using an acrylamide/bisacrylamide (10 %) gel
and transferred to a nitrocellulose membrane (GE
Healthcare, Germany) at 12 V for 20 min in a semi-dry
Trans-Blot Turbo system (Bio-Rad, Hercules, CA). After
blocking the membranes in 5 % skimmed milk in TBS-T
(10 mM), they were incubated with the appropriate pri-
mary antibodies, against α-actin (1A4) (1:2000, sc-32251,
Santa Cruz Biotechnology, CA, USA), glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (1:20,000; Sigma,
St. Louis, MO), fibronectin (1:1000, F7387, Sigma, St.
Louis, MO), lamin A/C (1:500, Cell Signaling Technology,
Boston, USA), pSmad2, Smad2, and TGFBR2 (1:2000;
Santa Cruz Biotechnology, CA, USA) overnight at 4 °C.
Membranes were washed in TBS-T (10 mM) and incu-
bated for 1 h at room temperature with secondary
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fluorescent antibodies IRDye 800 goat anti-rabbit and
IRDye 600 goat anti-mouse (1:15,000; LI-COR Biosci-
ences, Lincoln, NE). They were washed with TBS-T
(10 mM) and scanned using Odyssey Infrared Imaging
system (LI-COR Biosciences, Lincoln, NE). Protein quan-
tity was measured by band intensity using ImageJ 1.48
software.
Sircol Collagen Assay
Secreted collagen proteins I-V were detected in culture
medium using the Sircol Collagen Assay (S1000; Bioco-
lor, Carrickfergus, UK), according to the manufacturer’s
instructions.
Quantification of mRNA and miRNA expression
Total RNA and miRNA were extracted from HDFs or
skin samples of mice using miRNeasy Mini Kit (Qiagen,
CA, USA) and screened for purity and concentration in
a Nanodrop-1000 Spectrophotometer (Thermo Scien-
tific). Plasma miRNA was extracted from blood using
miRCURYTM RNA Isolation Kit—Biofluids and UniSp2
Spike-in RNA (Exiqon, Vedbaeck, Denmark). RT was
carried out with 500 ng of total RNA using the
iScriptTM cDNA Synthesis Kit (Bio-Rad, Hercules, CA).
Quantitative RT-PCR was carried out with the iQ™SYBR
Green Supermix (Bio-Rad, Hercules, CA), using specific
primers for mRNA amplification (Sigma, St. Louis, MO)
and miRNA LNA PCR primers for miR-5p (Exiqon,
Vedbaeck, Denmark) for miRNA expression analysis.
qRT-PCR was performed in a 96-well Bio-Rad CFX96
RT-PCR System with a C1000 Thermal Cycler (Bio-Rad,
Hercules, CA). A Ct value was obtained from each amp-
lification curve using CFX96 Analysis Software provided
by the manufacturer. Relative mRNA and miRNA ex-
pression was determined using the 2−ΔΔCt method [61].
GAPDH, snRNAU6, or UniSp-2 gene expression levels
in each sample were used for normalization, respectively.
The sequences of the primers were human GAPDH: for-
ward: 5′-GAGTCAACGGATTTGGTCGT-3′, reverse: 5′-
TTGATTTTGGAGGGATCTCG-3′; human Smad7: for-
ward: 5′-AGAGGCTGTGTTGCTGTGAA-3′, reverse:
5′-AAATCCATCGGGTATCTGGA-3′; human TGFBR1:
forward: 5′-TGGAGAGGAAAGTGGCGGGGAG-3′,
reverse: 5′-GCCTCACGGAACCACGAACG-3′; human
Col1α1: forward: 5′-CGGACGACCTGGTGAGAGA-3′,
reverse: 5′-CATTGTGTCCCCTAATGCCTT-3′; human
FN: forward: 5′-GTGTTGGGAATGGTCGTGGGGAAT
G-3′, reverse: 5′-CCAATGCCACGGCCATAGCAGTAG
C-3′; human α-SMA: forward: 5′-TTCAATGTCCCAGC
CATGTA-3′, reverse: 5′-GAAGGAATAGCCACGCTC
AG-3′; and human TGFBR2: forward: 5′-CCATGTCT
CACAGCCAGCTA-3′, reverse: 5′-CCAGGAGAAATAA
GGGCACA-3′.
Immunofluorescence cell staining
HDF cells were seeded onto 24-well plates containing
10-mm-diameter glass coverslips. They were transfected
with 40-nM pre-miRs. After 24-h starvation, cells were in-
cubated with 5 ng/ml TGF-β1 (R&D Systems, Minneapolis,
MN) for the indicated times. After treatments, cells were
washed briefly with cold PBS for three times and fixed
with 4 % paraformaldehyde for 20 min. Then, the cell
membrane was permeabilized by Triton X-100 (0.25 %) in
PBS for 5 min and blocked by FBS (10 %) for 1 h, at 37 °C.
The cells were incubated with anti-α-actin (1A4) (1:2000,
sc-32251, Santa Cruz Biotechnology) or anti-Smad2/3
(1:1000, 610843, BD Biosciences) overnight at 4 °C and
subsequently incubated with FITC-conjugated anti-mouse
or goat anti-rabbit antibody for 1 h. Cells were washed
with PBS and nuclei were stained with 4′,6-diamidino-2-
phenylindole (DAPI) and F-actin with phalloidin (1:1000,
Roche Molecular Biochemicals, Mannheim, Germany) for
5 min at room temperature. The coverslips were mounted
on slides using Mowiol (Calbiochem, Nottingham, U.K.).
Immunofluorescence was analyzed using a fluorescence
microscope (Nikon 80i, Japan).
Lentiviral vector construct
The lentivector-based miRNA precursor constructs ex-
pressing the miR-9-5p (lenti-miR-9) (MMIR-9-1-PA-1)
and the scramble negative control (lenti-SC) (MMIR-
000-PA-1) were purchased from SBI System Biosciences
(Mountain View, CA). Pseudoviral particles were pre-
pared using the pPACK-F1 Lentivector packaging system
(SBI System Biosciences, Mountain View, CA) and HEK
293T producer cell line. The titration of pseudoviral par-
ticles generated with the lentiviral vectors was deter-
mined by calculating the percentage of positive green
fluorescent protein (GFP) expression cells by flow cy-
tometry in a BD FACS CantoTM II High Throughput
Sampler flow cytometer (Becton Dickinson Bioscience,
Franklin Lakes, NJ) 72 h after infection. The lentivirus
titers were calculated as described [62] and expressed in
infection units (ifu)/ml.
Mouse model of bleomycin-induced dermal fibrosis and
in vivo delivery of lentiviral vectors
Mice were housed in the animal facility at CBMSO, in
accordance with EU regulations. Skin fibrosis was induced
in C57BL/6 mice by daily subcutaneous injections of bleo-
mycin, in accordance with previously published protocols
[63, 64]. A dose of 1 × 108 ifu/ml of lentivirus (lenti-miR-9
or lenti-SC) in 40 μl saline serum was subcutaneously de-
livered 4 days before bleomycin administration. Two
groups of six mice were injected on a daily basis with 10 μg
bleomycin (Sigma, St. Louis, MO) for 4 weeks, respectively.
Saline solution was used as vehicle in control groups of
mice. Mice were killed by cervical dislocation, and the back
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skin was removed and processed for histological examin-
ation. Animals were handled in agreement with the Guide
for the Care and Use of Laboratory Animals contained in
Directive 2010/63/EU of the European Parliament. Ap-
proval was granted by the local ethics review board of the
Centro de Biología Molecular “Severo Ochoa.”
Hematoxylin and eosin and Masson’s trichrome stainings
Skin samples of mice in the bleomycin or saline group were
quickly dissected and immersed in 4 % neutral buffered
formalin for 24 h and stained with Masson’s trichrome or
hematoxylin/eosin staining as described previously [65].
Statistical analysis
Data were analyzed using non-parametric tests. The dif-
ference between two independent groups was examined
with Mann-Whitney test, while more than two groups
were compared with Kruskall-Wallis test. A P value of
0.05 or less was considered statistically significant. Data
were analyzed using GraphPad Prism 5.0 (GraphPad
Software, La Jolla, CA, USA).
Additional file
Additional file 1: Figure S1. miR-9-5p does not affect TGF-β-induced
TGFBR1 and Smad7 expression and attenuates long-term Smad2
phosphorylation. (A) qRT-PCR analysis for mRNA expression of TGFBR1 in
HDF transfected with 40-nM pre-miR-9-5p or pre-miR-NC treated with
TGF-β1 (5 ng/ml) for the indicated times. (B) qRT-PCR analysis for mRNA
expression of Smad7 in HDF transfected with 40-nM pre-miR-9-5p or
pre-miR-NC treated with TGF-β1 (5 ng/ml) for the indicated times. The bar
graph shows values after correction by GAPDH expression and normalized
to control conditions. (C) Western blot analysis (left) and quantification (right)
of pSmad2 protein levels in HDF cells transfected with 40-nM pre-miR-9-5p
or pre-miR-NC and treated with TGF-β1 (5 ng/ml) at the indicated times
(a.u., arbitrary units). The bar graph shows values after correction by Smad2
expression and normalized to control conditions. All bar graphs represent
mean ± SEM of three independent experiments, *P < 0.001 and ***P < 0.01
compared to control cells and #P < 0.05 compared to its corresponding
negative control time point.
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